Aclaris Therapeutics
ACRS
137 hedge funds and large institutions have $409M invested in Aclaris Therapeutics in 2026 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 41 increasing their positions, 40 reducing their positions, and 15 closing their positions.
367% more capital inflows, than outflows
Capital inflows: $145M | Capital outflows: $31.1M
126% more call options, than puts
Call options by funds: $2.57M | Put options by funds: $1.14M
120% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 15
13.27% more ownership
Funds ownership: 77.29% → 90.56% (+13%)
12% more funds holding
Funds holding: 122 → 137 (+15)
3% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 40
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deep Track Capital
Greenwich,
Connecticut
|
+$31.5M |
| 2 |
RA Capital Management
Boston,
Massachusetts
|
+$23M |
| 3 |
Frazier Life Sciences Management
Palo Alto,
California
|
+$16.6M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$11.3M |
| 5 |
KCM
Kalehua Capital Management
Dallas,
Texas
|
+$6.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vivo Capital
Palo Alto,
California
|
-$7.5M |
| 2 |
D.E. Shaw & Co
New York
|
-$4.03M |
| 3 |
Morgan Stanley
New York
|
-$2.26M |
| 4 |
Renaissance Technologies
New York
|
-$2.1M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.97M |
ACRS Hedge Fund Activity: Q1 2026 in Review
137 of the 8,244 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2026, worth a combined $409M — up 62% from $252M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ACRS positions and 15 closed out — a net gain of 18 holders — while 41 added to existing stakes and 40 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $31.5M. The largest seller was Vivo Capital, cutting an estimated $7.5M.
- 137 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2026, up from 122 in Q4 2025.
- Funds reported $409M of Aclaris Therapeutics stock for Q1 2026, up 62% quarter-over-quarter.
- 33 funds opened new Aclaris Therapeutics positions in Q1 2026 and 15 closed out, a net change of +18 holders.
- The largest Aclaris Therapeutics buyer in Q1 2026 was Deep Track Capital, an estimated $31.5M added.
- The largest Aclaris Therapeutics seller in Q1 2026 was Vivo Capital, an estimated $7.5M sold.
Based on aggregated 13F filings for Q1 2026.